Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

75
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular...
75
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

45
Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1...
45
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

5.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.5K
Insulin: Biosynthesis, Chemistry, and Preparation01:25

Insulin: Biosynthesis, Chemistry, and Preparation

2.1K
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
2.1K
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

1.3K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.3K
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

17
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
17

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimization of Liver Graft Function Using the CEPT Cocktail (Chroman-1, Emricasan, Polyamine, and Trans-ISRIB) in a Simulated Transplant Model.

Organ medicine·2026
Same author

Kidney Transplantation in Two Highly Sensitized Candidates after CAR T-Cell Therapy.

The New England journal of medicine·2026
Same author

The American Society of Transplant Surgeons and American Journal of Transplantation at 25 years: Where we have been and where we will go.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026
Same author

Platelet Factor 4: A Novel Therapeutic Inhibitor for Experimental Neovascular Age-Related Macular Degeneration.

Frontiers in bioscience (Landmark edition)·2026
Same author

AI-enabled proactive health education: perceptions of public health students - a qualitative study.

BMC medical education·2026
Same author

Human islet isolation optimization: Insights from donor and isolation procedural factors.

Cell transplantation·2026
Same journal

Research advances and application prospects of CAR-T therapy in the treatment of age-related diseases.

Frontiers in immunology·2026
Same journal

Machine learning-driven identification and immunohistochemical validation of an integrated immune-inflammatory phenotype for disease-free survival stratification in breast cancer.

Frontiers in immunology·2026
Same journal

Modified treatment protocol for pediatric systemic lupus erythematosus-associated hemophagocytic lymphohistiocytosis with central nervous system involvement: a case report.

Frontiers in immunology·2026
Same journal

Exploratory characterization of IgG1/IgG4 glycosylation and monocyte-derived dendritic cell responses in esophageal squamous cell carcinoma.

Frontiers in immunology·2026
Same journal

JAK-STAT pathway-associated skin diseases: a refined functional framework for inflammatory skin diseases.

Frontiers in immunology·2026
Same journal

Cross-talk among novel programmed cell death pathways: a decisive network in renal ischemia-reperfusion injury.

Frontiers in immunology·2026
See all related articles

Related Experiment Video

Updated: May 1, 2026

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice
10:03

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

Published on: November 18, 2022

2.1K

Immune modulation for β-cell replacement in type 1 diabetes.

Qin Yang1, Yuanhui Song1, James F Markmann1

  • 1Penn Transplant Institute, Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, United States.

Frontiers in Immunology
|April 30, 2026
PubMed
Summary
This summary is machine-generated.

Type 1 diabetes (T1D) treatment faces immune rejection challenges. New strategies target inflammation, alloimmunity, and autoimmunity for durable beta-cell replacement and cure.

Keywords:
immune engineeringimmune rejectionimmunomodulationislet microenvironmenttype 1 diabetesβ-cell replacement

More Related Videos

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

5.3K
High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model
11:31

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model

Published on: August 16, 2019

6.9K

Related Experiment Videos

Last Updated: May 1, 2026

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice
10:03

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

Published on: November 18, 2022

2.1K
Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

5.3K
High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model
11:31

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model

Published on: August 16, 2019

6.9K

Area of Science:

  • Immunology
  • Endocrinology
  • Regenerative Medicine

Background:

  • Type 1 diabetes (T1D) involves autoimmune destruction of pancreatic beta-cells, remaining incurable despite technological advances.
  • Beta-cell replacement via transplantation offers a path to physiological glycemic control but faces significant immune rejection barriers.
  • Existing strategies like immunosuppression or shielding have not ensured long-term graft survival due to complex immune responses.

Purpose of the Study:

  • To review current mechanistic insights into immune processes limiting beta-cell graft survival in T1D.
  • To organize emerging therapeutic strategies based on the specific immune rejection pathways they address.
  • To provide a framework for developing coordinated immunomodulatory approaches for durable beta-cell replacement.

Main Methods:

  • Synthesis of current mechanistic insights into immune responses against beta-cell grafts.
  • Categorization of emerging therapeutic strategies targeting innate inflammation, adaptive alloimmunity, humoral responses, and autoimmune recurrence.
  • Discussion of graft-intrinsic immune engineering, local immunomodulation, and systemic interventions.

Main Results:

  • Identified overlapping immune pathways (innate, adaptive, humoral, autoimmune memory) that hinder beta-cell graft survival.
  • Highlighted diverse therapeutic strategies including graft engineering, local immunomodulation, and systemic immune interventions.
  • Emphasized the need for coordinated strategies to overcome multiple immune barriers.

Conclusions:

  • Durable, immune-compatible beta-cell replacement for T1D requires addressing multiple, intertwined immunological barriers.
  • Emerging therapeutic strategies offer promise by targeting specific immune pathways.
  • A rational, coordinated immunomodulatory framework is essential for successful beta-cell transplantation in T1D.